Review Article

Advances in long-acting injectable antipsychotics: Focus on paliperidone palmitate

Pavan Rana

Department of Pharmacology, Global College of Pharmacy, Kahanpur, Punjab, India

Correspondence:
Pavan Rana, Department of Pharmacology, Global College of Pharmacy, Kahanpur, Punjab, India.
E-mail: pavan.rana88@gmail.com

How to cite this article: Rana P. Advances in long-acting injectable antipsychotics: Focus on paliperidone palmitate. Innov Pharm Planet 2023;11(1):6-10.

Source of Support: Nil.
Conflicts of Interest: None declared.

Date of Submission: 20-01-2023
Date of Revision: 10-02-2023
Date of Acceptance: 18-02-2023

ABSTRACT

Long-acting injectable antipsychotics (LAIAs) have emerged as a critical advancement in the treatment of schizophrenia and related psychotic disorders, offering a solution to the common issue of nonadherence associated with oral antipsychotics. Among these, paliperidone palmitate has gained prominence due to its favorable efficacy, safety profile, and flexible dosing options, available in both monthly and 3-month formulations. This review provides a comprehensive examination of the pharmacology, clinical efficacy, safety, and economic implications of paliperidone palmitate, highlighting its advantages over oral antipsychotics and first-generation LAIAs. Paliperidone palmitate exerts its effects through dopamine (D2) and serotonin (5HT2A) receptor antagonism, which helps in managing both the positive and negative symptoms of schizophrenia. Clinical trials and real-world studies demonstrate its effectiveness in reducing relapse rates, preventing hospitalizations, and improving treatment adherence compared to oral formulations. Furthermore, the availability of a 3-month dosing option has further enhanced patient satisfaction by reducing the frequency of administration. Despite its benefits, challenges such as initial loading doses and potential side effects, including weight gain and metabolic disturbances, require careful management. This review also explores the economic benefits of paliperidone palmitate, including its cost-effectiveness in reducing healthcare utilization. Finally, emerging research on its use in early intervention for schizophrenia and potential future advancements in LAIA formulations are discussed. This review underscores the critical role of paliperidone palmitate in enhancing treatment outcomes and advancing the long-term management of schizophrenia.

Keywords: Antipsychotic adherence, long-acting injectable antipsychotics, paliperidone palmitate, pharmacokinetics of paliperidone, relapse prevention, schizophrenia treatment

Introduction

Overview of long-acting injectable antipsychotic (LAIAs) definition and characteristics of LAIAs, emphasizing their role in psychiatric treatment.

Historical development of LAIAs, beginning with first-generation antipsychotics such as fluphenazine and haloperidol and transitioning to second-generation options such as paliperidone palmitate and others.[1]

Access this article online

Website: https://innovationaljournals.com/index.php/ip | e-ISSN: 2348-7275

DOI: 10.31690/ipplanet.2023.v011i01.002

Importance of LAIAs in managing schizophrenia and other psychotic disorders

Discussion on how LAIAs enhance treatment adherence, particularly in patients with schizophrenia and schizoaffective disorder, thereby reducing relapse rates and improving overall outcomes.[2]

Evidence supporting the effectiveness of LAIAs compared to oral antipsychotics in maintaining stability and reducing hospitalization rates.[3]

Limitations of oral antipsychotic therapy

Examination of adherence issues is associated with oral medications, including forgetfulness and stigma, which can lead to non-adherence rates as high as 50%.[2]

Overview of side effects related to oral antipsychotics that may discourage consistent use, such as extrapyramidal symptoms (EPS) and metabolic syndrome.[4]

Evolution of LAIAs

Description of the transition from first-generation to second-generation LAIAs, highlighting improvements in tolerability and dosing intervals.[4]

Innovations in formulation and administration techniques that enhance patient compliance and comfort, such as the introduction of monthly and quarterly injections.

Paliperidone Palmitate as a Case Study

Brief Introduction to Paliperidone Palmitate

Overview of paliperidone palmitate, including its pharmacological profile, dosing regimen, and unique characteristics compared to other LAIAs.[5]

Discussion on the availability of different formulations (monthly and three-monthly) and their implications for patient management.

Clinical evidence supporting paliperidone palmitate

Summary of key clinical trials demonstrating the efficacy of paliperidone palmitate in reducing disease severity and rehospitalizations in schizophrenia patients, with a focus on its safety profile compared to first-generation antipsychotics.[3]

Analysis of real-world studies indicating lower rates of relapse and better adherence outcomes associated with paliperidone palmitate compared to oral alternatives.

Objectives of the Review

To critically evaluate the advancements in LAIAs with a specific focus on paliperidone palmitate and its clinical implications.

To analyze the impact of these advancements on treatment adherence and patient outcomes in schizophrenia and other psychotic disorders.

To identify gaps in the current research regarding LAIAs and suggest areas for future investigation, particularly concerning patient preferences and pharmacogenetic factors influencing treatment response.[4,5]

This structured outline provides a comprehensive framework for discussing the advances in LAIAs, specifically focusing on paliperidone palmitate, while addressing both clinical implications and research opportunities.

Pharmacology of Paliperidone Palmitate

Mechanism of action

Paliperidone palmitate, an injectable formulation of paliperidone, exerts its therapeutic effects primarily through the antagonism of specific neurotransmitter receptors in the brain:

Dopamine (D2) Receptor Antagonism: Paliperidone palmitate acts as a central dopamine D2 receptor antagonist. This action is crucial in mitigating the positive symptoms of schizophrenia, such as hallucinations and delusions.[6]

Serotonin (5HT2A) Receptor Antagonism: In addition to its effects on dopamine receptors, paliperidone also antagonizes serotonin 5HT2A receptors. This dual action contributes to its efficacy in treating both positive and negative symptoms of schizophrenia, as well as reducing the risk of extrapyramidal side effects commonly associated with D2 antagonism alone.[7]

Pharmacokinetics and absorption

Dosing and Administration: Paliperidone palmitate is administered through intramuscular injection, with dosing options available for monthly or every 3 months. The typical initiation involves two injections within the 1st month (234 mg on day 1 and 156 mg on day 8), followed by a maintenance dose ranging from 39 mg to 234 mg monthly, depending on individual response and tolerability.

Drug Release and Plasma Levels: The formulation is designed for sustained release, utilizing nanocrystal technology that allows for a gradual dissolution and absorption into the bloodstream. This mechanism results in peak plasma levels being reached approximately 13 days after injection, with a serum half-life ranging from 25 to 49 days, facilitating a stable therapeutic effect over extended periods.

Metabolism and excretion

Paliperidone versus Risperidone Metabolism: Paliperidone is the active metabolite of risperidone, and its pharmacokinetics reflect a more favorable profile in terms of side effects. While risperidone undergoes extensive hepatic metabolism, paliperidone is primarily excreted unchanged, which may reduce the risk of drug interactions and variability in drug response among patients.[8]

Renal excretion: The excretion of paliperidone is predominantly renal, with about 60% of the administered dose eliminated through urine. This necessitates caution in patients with renal impairment, as reduced kidney function can lead to increased plasma levels and potential toxicity.[3]

This comprehensive overview of the pharmacology of paliperidone palmitate highlights its mechanism of action, pharmacokinetic properties, and metabolic pathways, underscoring its significance in the management of schizophrenia and related disorders.

Clinical Efficacy of Paliperidone Palmitate

Studies on acute and maintenance treatment

Paliperidone palmitate has been extensively studied for both acute and maintenance treatment of schizophrenia. Key findings from pivotal clinical trials include:

Efficacy in reducing symptoms: In four short-term, randomized, double-blind, placebo-controlled trials, paliperidone palmitate demonstrated significant efficacy in reducing symptoms of schizophrenia, as measured by the positive and negative syndrome scale total scores. The trials indicated that patients receiving paliperidone palmitate showed greater symptom improvement compared to those receiving placebo, particularly within the first few weeks of treatment.[9]

Comparison with Oral Antipsychotics and Other LAIAs: Paliperidone palmitate has been shown to be non-inferior to risperidone long-acting injection in several studies, indicating comparable efficacy in managing schizophrenia symptoms. This suggests that paliperidone palmitate can be an effective alternative to both oral antipsychotics and other LAIAs.

Relapse prevention

Effectiveness in preventing relapse: Long-term maintenance studies have shown that paliperidone palmitate is effective in preventing or delaying the time to first relapse in stable schizophrenia patients. It has been found to significantly reduce the risk of relapse compared to placebo, confirming its role in long-term management of the disorder.

Duration of symptom remission: Patients treated with paliperidone palmitate have demonstrated longer durations of symptom remission, with many achieving stable remission for extended periods. In a study comparing the 3-month formulation to the monthly formulation, both regimens showed similar relapse rates, indicating that paliperidone palmitate can maintain efficacy over longer dosing intervals.[10]

Dosing schedules: Monthly versus 3-month formulation

Efficacy and adherence data for both schedules: The monthly formulation (PP1M) and the 3-month formulation (PP3M) of paliperidone palmitate have been evaluated for their efficacy and adherence. A phase 3 study confirmed that the 3-month formulation is non-inferior to the monthly formulation in terms of relapse rates and symptom control, with both regimens exhibiting similar tolerability profiles. This flexibility in dosing schedules allows for improved adherence, as patients may prefer the less frequent dosing of the 3-month formulation.[11]

Paliperidone palmitate has demonstrated robust clinical efficacy in both acute and maintenance treatment of schizophrenia, with significant advantages in relapse prevention and patient adherence through flexible dosing options.

Safety and Tolerability Profile

Common adverse effects

Paliperidone palmitate is generally well tolerated, but certain adverse effects have been reported:

EPS: The incidence of EPS, including akathisia, has been documented in clinical trials, with rates typically below 10%. In specific studies, akathisia was the most frequently reported EPS event, occurring in less than 6% of patients.[7]

Weight gain and metabolic issues: Weight gain is a notable concern, with studies indicating that approximately 6% of patients experience a weight increase of more than 7% from baseline. In addition, metabolic syndrome risks, such as increased blood glucose and lipid levels, have been associated with paliperidone palmitate treatment.[7,8]

Injection Site Reactions: Injection site reactions have been reported in about 10% of cases, which is higher than the placebo group. These reactions can include pain, swelling, and redness at the injection site.[12]

Long-term safety data

Data on Tardive Dyskinesia: Long-term use of paliperidone palmitate has been associated with a lower incidence of tardive dyskinesia compared to some other antipsychotics. However, ongoing monitoring is essential as tardive dyskinesia can develop with prolonged treatment.[12]

Cardiovascular and Metabolic Risks over Time: Long-term studies have indicated a potential increase in cardiovascular and metabolic risks, particularly in patients with pre-existing conditions. Regular monitoring of weight, glucose, and lipid levels are recommended to mitigate these risks.[12]

Comparison to other LAIAs

Paliperidone palmitate's tolerability profile has been compared favorably with other LAIAs:

Comparative tolerability: When compared to aripiprazole and risperidone, paliperidone palmitate exhibits a similar or better safety profile concerning EPS and metabolic side effects. For instance, aripiprazole has been associated with lower rates of weight gain but may have other side effects that vary by patient.

Adherence and Patient Outcomes

Impact on treatment adherence

Paliperidone palmitate significantly improves treatment adherence compared to oral formulations:

Improvement over oral formulations: The convenience of monthly or quarterly injections reduces the burden of daily medication adherence,

which is often a challenge in managing schizophrenia. Studies have shown that LAIs like paliperidone palmitate lead to higher adherence rates and lower relapse rates compared to oral antipsychotics.[13]

Role of LAIs in reducing hospitalizations and improving quality of life: The use of paliperidone palmitate has been linked to a reduction in hospitalization rates and an overall improvement in quality of life for patients, as evidenced by various patient-reported outcomes.[13]

Patient preferences and satisfaction

Patient-reported outcomes and satisfaction levels: Patients generally report higher satisfaction levels with long-acting injectable formulations due to the reduced frequency of dosing and the associated decrease in the stigma of taking daily medication. Surveys indicate that many patients prefer LAIs over oral medications for their ease of use and effectiveness in managing symptoms.

Use in special populations

Elderly patients, adolescents, patients with substance use disorders: Paliperidone palmitate has been studied in various populations, including the elderly and adolescents. It has shown efficacy and safety in these groups, although careful monitoring is essential, particularly in patients with comorbid substance use disorders due to the potential for increased side effects and complications.

Economic and Healthcare System Implications

Cost effectiveness of paliperidone palmitate

Cost comparisons with other antipsychotics and hospitalization costs: Paliperidone palmitate has been shown to be cost effective when considering the reduction in hospitalization rates and the associated healthcare costs. Studies indicate that the overall economic burden of schizophrenia can be significantly lowered with effective LAI treatment.

Budget impact analysis for healthcare systems: Implementing paliperidone palmitate within healthcare systems can lead to substantial savings by reducing the need for acute care services and hospitalizations, thereby alleviating financial strain on healthcare resources.[12]

Healthcare utilization

Reduction in Hospitalization Rates: The introduction of paliperidone palmitate has been associated with a notable decrease in hospitalization rates among patients with schizophrenia, contributing to improved patient outcomes and reduced healthcare costs.

Impact on Emergency Department Visits and Overall Healthcare Burden: Patients using paliperidone palmitate have shown fewer emergency department visits related to psychiatric crises, indicating a positive impact on overall healthcare utilization and burden on emergency services.

Challenges and Limitations in the Use of Paliperidone Palmitate

Dosing and administration issues

Requirement for loading doses: The initial treatment phase requires loading doses, which can be a barrier for some patients. Proper education and management strategies are necessary to ensure adherence during this phase.

Management of missed doses: Strategies for managing missed doses are critical, as delays in administration can lead to symptom exacerbation and increased risk of relapse.

Side effect profile

Addressing patient concerns regarding weight gain and metabolic issues: Clinicians must proactively address concerns related to weight gain and metabolic syndrome, providing education and monitoring to mitigate these risks.

Patient specific factors

Tailoring Treatment to Individual Needs: Individual patient factors, such as renal impairment and comorbidities, must be considered when prescribing paliperidone palmitate to optimize treatment outcomes and minimize adverse effects.

Future Directions and Emerging Research

Development of newer LAIAs

Innovations in drug delivery systems: Ongoing research is focused on developing newer formulations and drug delivery systems that may enhance the efficacy and tolerability of LAIs, including paliperidone palmitate.

Potential future modifications to dosing schedules: Future studies may explore alternative dosing schedules that could further improve adherence and patient satisfaction.[13]

Role of paliperidone palmitate in early intervention

Use in prodromal schizophrenia and first-episode psychosis: Research is being conducted on the efficacy of paliperidone palmitate in early intervention settings, potentially preventing the progression of schizophrenia in at-risk populations.

Long-term outcomes

Ongoing research on long-term impact: Studies are investigating the long-term effects of paliperidone palmitate on mortality, cognitive function, and social outcomes, aiming to provide a comprehensive understanding of its benefits over time.[13]

Conclusion

Paliperidone palmitate represents a significant advancement in the treatment of schizophrenia, with demonstrated efficacy, safety, and improved adherence compared to traditional oral formulations.

Clinical implications

The findings underscore the importance of personalized treatment approaches that consider individual patient needs and preferences, as well as the role of LAIs in the evolving landscape of schizophrenia treatment.

Role of LAIAs in the evolving landscape of schizophrenia treatment

As the understanding of schizophrenia and its management continues to evolve, paliperidone palmitate and other LAIs will play a crucial role in improving patient outcomes and reducing the overall burden of this complex disorder on healthcare systems.

References

1. Hu A. A practical review of long-acting injectable antipsychotics. US Pharm 2024;49:HS1-6.
2. Janzen D, Bolton JM, Leong C, Kuo IF, Alessi-Severini S. Second-generation long-acting injectable antipsychotics and the risk of treatment failure in a population-based cohort. Front Pharmacol 2022;13:879224.
3. Morris MT, Tarpada SP. Long-acting injectable paliperidone palmitate: A review of efficacy and safety. Psychopharmacol Bull 2017;47:42-52.
4. VandenBerg AM. An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use. Mental Health Clin 2022;12:270-81.
5. Markowicz-Piasecka M, Kubisiak M, Asendrych-Wicik K, Kołodziejczyk M, Grzelińska J, Fabijańska M, *et al*. Long-acting injectable antipsychotics-a review on formulation and in vitro dissolution. Pharmaceutics 2023;16:28.
6. Gilday E, Nasrallah HA. Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia. Rev Recent Clin Trials 2012;7:2-9.
7. Kim S, Solari H, Weiden PJ, Bishop JR. Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults. Patient Prefer Adherence 2012;6:533-45.
8. Chue P, Chue J. A review of paliperidone palmitate. Expert Rev Neurother 2012;12:1383-97.
9. Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin 2010;26:377-87.
10. Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Janik A, *et al*. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: A randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol 2016;19:pyw018.
11. Bossie CA, Sliwa JK, Ma YW, Fu DJ, Alphs L. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: Post-hoc analyses of a randomized, double-blind clinical trial. BMC Psychiatry 2011;11:79.
12. Cicala G, de Filippis R, Barbieri MA, Cutroneo PM, De Fazio P, Schoretsanitis G, *et al*. Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database. Front Psychiatry 2023;14:1130636.
13. Coppola D, Liu Y, Gopal S, Remmerie B, Samtani MN, Hough DW, *et al*. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry 20212;12:1-14.